Lucid Diagnostics (LUCD), a majority-owned subsidiary of PAVmed (PAVM), announced that it performed a record number of commercial EsoGuard Esophageal DNA tests in the second quarter of 2024. The 3,174 tests represent a 31% increase sequentially from the first quarter. Lucid also reported that it held a productive meeting with CMS Medicare Administrative Contractor Palmetto GBA’s Molecular Diagnostics Program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD: